Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446696 | 0.86 | MEN1 (0.62) | CES2ALDH1A1HTTLMNAFAAH | |
| SCHEMBL4433152 | 0.82 | CES2 (1.00) | CES2NPC1RAB9A | |
| SCHEMBL30192907 | 0.82 | CES2 (1.00) | CES2NPC1RAB9A | |
| SCHEMBL4440938 | 0.79 | CES2 (0.74) | CES2ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL15339808 | 0.79 | CES2 (0.74) | CES2HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL25987647 | 0.79 | SMN1; SMN2 (0.74) | ALDH1A1LMNAFAAHMEN1KMT2A | |
| SCHEMBL24013409 | 0.78 | CES2 (0.74) | CES2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL28495982 | 0.76 | HTT (0.60) | ALDH1A1HTTLMNAFAAHMEN1 | |
| SCHEMBL4443290 | 0.76 | CES2 (0.68) | CES2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28496879 | 0.75 | NPC1 (0.65) | ALDH1A1HTTLMNAFAAHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012058115-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | CRAVATT BENJAMIN (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | CES2 679/4885ALDH1A1 444/4885HTT 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.